Promethera's Product Development team will be present at the upcoming AASLD meeting in Boston, contact us if you want to meet up to hear about the latest developments of HepaStem for the treatment of fibro-inflammatory liver diseases.
Also, Pr. F. Nevens, MD, PhD, will present the abstract : "SAFETY AND TOLERABILITY OF LIVER-DERIVED STEM CELLS (HEPASTEM™) INFUSED IN PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) OR ACUTE DECOMPENSATION (AD) AT RISK OF DEVELOPING ACLF: A EUROPEAN PHASE I/IIa OPEN-LABELLED STUDY" during the Oral Session - Parallel 13: Cellular and Molecular Biology of the Liver at The Liver Meeting 2019. This Parallel Session is scheduled on Sunday, November 10, 2019 at 4:30 PM.
Don't miss it!